A B Federici - Concepedia

Author

A B Federici

Also Known As

A B Federici, A. B Federici, A. B. FEDERICI, A. B. Federici, A.B. FEDERICI, A.B. Federici, Anna Lecchi, Augusto B Federici, Augusto B. Federici

Publications

Citations

H-Index

Concepts

All Affiliations

University of Milan Lund University Université de Lille Leiden University Medical Center Ospedale Maggiore

About

A B Federici is an author at University of Milan specializing in medicine, hematology, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.2K
2	Public Health	5	5	1.1K
3	Engineering	1	1	83
4	Natural Sciences	1	1	83
5	Biochemistry	1	1	83

A B Federici

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD) Alberto Tosetto, Francesco Rodeghiero, Giancarlo Castaman, Journal of Thrombosis and Haemostasis ThrombosisType 1HematologyDiagnosisPathology	2006	523
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study Francesco Rodeghiero, Giancarlo Castaman, Alberto Tosetto, Journal of Thrombosis and Haemostasis ThrombosisType 1Venous ThrombosisDiscriminant PowerHematology	2005	353
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD Jeroen Eikenboom, Vincent Marion, Hein Putter, Journal of Thrombosis and Haemostasis Type 1Genetic DisorderGeneticsInherited Metabolic DiseaseGenetic Epidemiology	2006	118
Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods Jenny Goudemand, I. Scharrer, Erik Berntorp, Journal of Thrombosis and Haemostasis Pharmacokinetic StudiesVirus-inactivation/removal MethodsHematologyImmunologyMedicine	2005	87
Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. A B Federici, John H. Elder, L. De Marco, Journal of Clinical Investigation Total HexoseProtein FunctionEngineeringVon Willebrand FactorBiochemistry	1984	83
Acquired von Willebrand syndrome 2004: International Registry Ulrich Budde, Jacob H. Rand, A B Federici Hämostaseologie Von Willebrand SyndromeImmunologyDiagnosisPathologyCollagen Binding	2004	52
Gynaecological and obstetrical problems in women with different bleeding disorders Simona Maria Siboni, Marta Spreafico, Leonardo Calò, Haemophilia Reproductive HealthGynecologyMenstrual CycleThrombosisHematology	2009	47
A type 2b von Willebrand disease mutation (Ile546-->Val) associated with an unusual phenotype. A B Federici, Pier Mannuccio Mannucci, Federica Stabile, PubMed GeneticsGenetic EpidemiologyImmunologyPathologyMature Vwf Subunit	1997	30
Markers of vascular injury in Behçet's disease associated with retinal vasculitis. Paola Pivetti‐Pezzi, Roberta Priori, G. Catarinelli, PubMed Vascular DiseaseOcular DiseaseVasculitisImmunologyPathology	1992	20
Role for platelet von willebrand factor in supporting platelet‐vessel wall interactions in von willebrand disease R. Castillo, Ginés Escolar, Antonio Ordinas, American Journal of Hematology ImmunologyPlatelet VwfPathologyVon Willebrand DiseaseThrombosis	1989	18

Page 1